Murray Barclay

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8591234/publications.pdf

Version: 2024-02-01

187 papers	16,651 citations	30070 54 h-index	16183 124 g-index
191 all docs	191 docs citations	191 times ranked	22037 citing authors

#	Article	IF	Citations
1	Hostâ€“microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature, 2012, 491, 119-124.	27.8	4,038
2	Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nature Genetics, 2010, 42, 1118-1125.	21.4	2,284
3	Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nature Genetics, 2011, 43, 246-252.	21.4	1,201
4	A suggested approach to onceâ€daily aminoglycoside dosing.. British Journal of Clinical Pharmacology, 1995, 39, 605-609.	2.4	296
5	High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. Nature Genetics, 2015, 47, 172-179.	21.4	280
6	Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Alimentary Pharmacology and Therapeutics, 2000, 14, 963-978.	3.7	268
7	Review article: consensus statements on therapeutic drug monitoring of antiâ€tumour necrosis factor therapy in inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 2017, 46, 1037-1053.	3.7	225
8	High incidence of CrohnÊ¼s disease in Canterbury, New Zealand: Results of an epidemiologic study. Inflammatory Bowel Diseases, 2006, 12, 936-943.	1.9	219
9	Perianal Disease Predicts Changes in Crohn's Disease Phenotype-Results of a Population-Based Study of Inflammatory Bowel Disease Phenotype. American Journal of Gastroenterology, 2008, 103, 3082-3093.	0.4	205
10	Azathioprine and 6â€mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 1149-1157.	2.8	201
11	Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis and Rheumatism, 2011, 63, 412-421.	6.7	199
12	Populationâ€based cases control study of inflammatory bowel disease risk factors. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 325-333.	2.8	192
13	Deep Resequencing of GWAS Loci Identifies Rare Variants in CARD9, IL23R and RNF186 That Are Associated with Ulcerative Colitis. PLoS Genetics, 2013, 9, e1003723.	3.5	185
14	The Spectrum of Perianal Crohnâ€™s Disease in a Population-Based Cohort. Diseases of the Colon and Rectum, 2012, 55, 773-777.	1.3	182
15	Aminoglycosides--50 years on. British Journal of Clinical Pharmacology, 1995, 39, 597-603.	2.4	170
16	Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism, 2008, 58, 3299-3308.	6.7	161
17	IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes. Nature Communications, 2018, 9, 2427.	12.8	159
18	Populationâ€based epidemiology study of autoimmune hepatitis: A disease of older women?. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 1681-1686.	2.8	157

#	Article	IF	Citations
19	Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiology and Drug Safety, 2004, 13, 563-567.	1.9	142
20	Confirmation of association of IRGM and NCF4 with ileal Crohn's disease in a population-based cohort. Genes and Immunity, 2008, 9, 561-565.	4.1	142
21	Reasons for Failure to Diagnose Colorectal Carcinoma at Colonoscopy. Endoscopy, 2004, 36, 499-503.	1.8	141
22	The therapeutic monitoring of antimicrobial agents. British Journal of Clinical Pharmacology, 1999, 47, 23-30.	2.4	132
23	Has Toll-Like Receptor 4 Been Prematurely Dismissed as an Inflammatory Bowel Disease Gene? Association Study Combined With Meta-Analysis Shows Strong Evidence for Association. American Journal of Gastroenterology, 2007, 102, 2504-2512.	0.4	116
24	Systematic review with metaâ€analysis: SARSâ€CoVâ€2 stool testing and the potential for faecalâ€oral transmission. Alimentary Pharmacology and Therapeutics, 2020, 52, 1276-1288.	3.7	113
25	The therapeutic monitoring of antimicrobial agents. British Journal of Clinical Pharmacology, 2001, 52, 35-43.	2.4	111
26	Submental Surface Electromyographic Measurement and Pharyngeal Pressures During Normal and Effortful Swallowing. Archives of Physical Medicine and Rehabilitation, 2005, 86, 2144-2149.	0.9	111
27	IL23R R381Q and ATG16L1 T300A Are Strongly Associated With Crohn's Disease in a Study of New Zealand Caucasians With Inflammatory Bowel Disease. American Journal of Gastroenterology, 2007, 102, 2754-2761.	0.4	109
28	Adaptive resistance following single doses of gentamicin in a dynamic in vitro model. Antimicrobial Agents and Chemotherapy, 1992, 36, 1951-1957.	3.2	107
29	Once Daily Aminoglycoside Therapy. Clinical Pharmacokinetics, 1999, 36, 89-98.	3.5	107
30	Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics and Genomics, 2004, 14, 779-781.	5.7	107
31	A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Annals of the Rheumatic Diseases, 2017, 76, 1522-1528.	0.9	107
32	Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. British Journal of Clinical Pharmacology, 2006, 62, 453-456.	2.4	106
33	Lithium associated thyrotoxicosis: a report of 14 cases, with statistical analysis of incidence. Clinical Endocrinology, 1994, 40, 759-764.	2.4	103
34	Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving longâ€term methotrexate treatment. Arthritis and Rheumatism, 2009, 60, 2248-2256.	6.7	94
35	Evidence of interaction of CARD8 rs2043211 with NALP3 rs35829419 in Crohn's disease. Genes and Immunity, 2010, 11, 351-356.	4.1	92
36	What is the Evidence for Once-Daily Aminoglycoside Therapy?. Clinical Pharmacokinetics, 1994, 27, 32-48.	3.5	84

#	Article	IF	Citations
37	Thiopurine S -methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2003, 18, 395-400.	3.7	84
38	Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis. Journal of Antimicrobial Chemotherapy, 1996, 37, 1155-1164.	3.0	83
39	Pharmacoeconomic Analyses of Azathioprine, Methotrexate and Prospective Pharmacogenetic Testing for the Management of Inflammatory Bowel Disease. Pharmacoeconomics, 2006, 24, 767-781.	3.3	83
40	Association of Higher DEFB4 Genomic Copy Number With Crohn's Disease. American Journal of Gastroenterology, 2010, 105, 354-359.	0.4	83
41	Aminoglycoside Adaptive Resistance. Drugs, 2001, 61, 713-721.	10.9	79
42	Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. Clinical Pharmacology and Therapeutics, 2001, 70, 217-227.	4.7	78
43	Dietary factors in chronic inflammation: Food tolerances and intolerances of a New Zealand Caucasian Crohn's disease population. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2010, 690, 123-138.	1.0	78
44	Thiopurine Dose in Intermediate and Normal Metabolizers of Thiopurine Methyltransferase May Differ Three-Fold. Clinical Gastroenterology and Hepatology, 2008, 6, 654-660.	4.4	77
45	Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving longâ€term methotrexate therapy. Arthritis and Rheumatism, 2010, 62, 359-368.	6.7	77
46	Comparative performances of machine learning methods for classifying Crohn Disease patients using genome-wide genotyping data. Scientific Reports, 2019, 9, 10351.	3.3	75
47	Differential association of two PTPN22 coding variants with CrohnÊ¼s disease and ulcerative colitis. Inflammatory Bowel Diseases, 2011, 17, 2287-2294.	1.9	73
48	Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives. Journal of Crohn's and Colitis, 2018, 12, 610-620.	1.3	67
49	A suggested approach to once-daily aminoglycoside dosing. British Journal of Clinical Pharmacology, 1995, 39, 605-9.	2.4	63
50	Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice. Internal Medicine Journal, 2005, 35, 580-585.	0.8	61
51	Use and Predictors of Oral Complementary and Alternative Medicine by Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2013, 19, 767-778.	1.9	60
52	KCNN4 Gene Variant Is Associated With Ileal Crohn's Disease in the Australian and New Zealand Population. American Journal of Gastroenterology, 2010, 105, 2209-2217.	0.4	59
53	Efficacies of different vancomycin dosing regimens against Staphylococcus aureus determined with a dynamic in vitro model. Antimicrobial Agents and Chemotherapy, 1994, 38, 2480-2482.	3.2	57
54	Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate. Pharmacogenetics and Genomics, 2010, 20, 367-376.	1.5	57

#	Article	IF	Citations
55	Clinical and Genetic Risk Factors for Perianal Crohn's Disease in a Population-Based Cohort. American Journal of Gastroenterology, 2012, 107, 589-596.	0.4	57
56	Simultaneous quantification of amoxycillin and metronidazole in plasma using high-performance liquid chromatography with photodiode array detection. Biomedical Applications, 1999, 731, 261-266.	1.7	54
57	Incidence of Mycobacterium avium Subspecies paratuberculosis in a Population-Based Cohort of Patients With Crohn's Disease and Control Subjects. American Journal of Gastroenterology, 2008, 103, 1168-1172.	0.4	54
58	Effects of Changing from Oral to Subcutaneous Methotrexate on Red Blood Cell Methotrexate Polyglutamate Concentrations and Disease Activity in Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2011, 38, 2540-2547.	2.0	54
59	Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status. Pharmacogenetics and Genomics, 2003, 13, 627-632.	5.7	53
60	Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study. Annals of the Rheumatic Diseases, 2017, 76, 2065-2070.	0.9	53
61	Single nucleotide polymorphism in the tumor necrosis factor-alpha gene affects inflammatory bowel diseases risk. World Journal of Gastroenterology, 2008, 14, 4652.	3.3	50
62	Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration?. British Journal of Clinical Pharmacology, 2001, 51, 627-630.	2.4	49
63	High <scp>TPMT</scp> enzyme activity does not explain drug resistance due to preferential 6â€methylmercaptopurine production in patients on thiopurine treatment. Alimentary Pharmacology and Therapeutics, 2012, 35, 1181-1189.	3.7	49
64	Red Blood Cell Methotrexate Polyglutamate Concentrations in Inflammatory Bowel Disease. Therapeutic Drug Monitoring, 2007, 29, 619-625.	2.0	48
65	Relationship Between Serum Urate and Plasma Oxypurinol in the Management of Gout: Determination of Minimum Plasma Oxypurinol Concentration to Achieve a Target Serum Urate Level. Clinical Pharmacology and Therapeutics, 2011, 90, 392-398.	4.7	48
66	Burnout prevalence in New Zealand's public hospital senior medical workforce: a cross-sectional mixed methods study. BMJ Open, 2016, 6, e013947.	1.9	48
67	Gender-stratified analysis of DLG5 R30Q in 4707 patients with Crohn disease and 4973 controls from 12 Caucasian cohorts. Journal of Medical Genetics, 2007, 45, 36-42.	3.2	47
68	IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance. Pharmacogenomics Journal, 2007, 7, 312-317.	2.0	47
69	The use ofÂlow dose methotrexate inÂrheumatoid arthritisâ€”are we entering aÂnew era ofÂtherapeutic drug monitoring andÂpharmacogenomics?. Biomedicine and Pharmacotherapy, 2006, 60, 678-687.	5.6	46
70	Predicting allopurinol response in patients with gout. British Journal of Clinical Pharmacology, 2016, 81, 277-289.	2.4	46
71	Experience of onceâ€daily aminoglycoside dosing using a target area under the concentrationâ€time curve. Australian and New Zealand Journal of Medicine, 1995, 25, 230-235.	0.5	45
72	Combination Immunosuppression in IBD. Inflammatory Bowel Diseases, 2018, 24, 539-545.	1.9	45

#	Article	IF	Citations
73	Impaired response or insufficient dosage?â€"Examining the potential causes of â€œinadequate responseâ€•to allopurinol in the treatment of gout. Seminars in Arthritis and Rheumatism, 2014, 44, 170-174.	3.4	43
74	Update on thiopurine pharmacogenetics in inflammatory bowel disease. Pharmacogenomics, 2015, 16, 891-903.	1.3	43
75	How to prevent allopurinol hypersensitivity reactions?. Rheumatology, 2018, 57, i35-i41.	1.9	43
76	Surveillance for Dysplasia in Patients With Inflammatory Bowel Disease: A National Survey of Colonoscopic Practice in New Zealand. Diseases of the Colon and Rectum, 2004, 47, 314-322.	1.3	42
77	Severe hepatotoxicity with high 6-methylmercaptopurine nucleotide concentrations after thiopurine dose escalation due to low 6-thioguanine nucleotides. European Journal of Gastroenterology and Hepatology, 2008, 20, 1238-1242.	1.6	41
78	Azathioprine and allopurinol: A twoâ€•edged interaction. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 653-655.	2.8	41
79	Effect of inflammatory bowel disease classification changes on NOD2 genotypeâ€“phenotype associations in a population-based cohort. Inflammatory Bowel Diseases, 2007, 13, 1220-1227.	1.9	40
80	Trinucleotide repeat variants in the promoter of the thiopurine S-methyltransferase gene of patients exhibiting ultra-high enzyme activity. Pharmacogenetics and Genomics, 2008, 18, 434-438.	1.5	40
81	Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice. Rheumatology, 2012, 51, 1670-1676.	1.9	38
82	Correlation Between Trough Plasma Dabigatran Concentrations and Estimates of Glomerular Filtration Rate Based on Creatinine and Cystatin C. Drugs in R and D, 2014, 14, 113-123.	2.2	38
83	Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (<scp>AAA</scp> Study). Alimentary Pharmacology and Therapeutics, 2018, 47, 1092-1102.	3.7	38
84	Allopurinol might improve response to azathioprine and 6â€•mercaptopurine by correcting an unfavorable metabolite ratio. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 49-54.	2.8	37
85	Genetic analysis of MDR1 and inflammatory bowel disease reveals protective effect of heterozygous variants for ulcerative colitis. Inflammatory Bowel Diseases, 2009, 15, 1784-1793.	1.9	36
86	Two cases of thiopurine methyltransferase (TPMT) deficiency ? a lucky save and a near miss with azathioprine. British Journal of Clinical Pharmacology, 2006, 62, 473-476.	2.4	34
87	A Simple High-Performance Liquid Chromatography Method for Simultaneous Determination of Three Triazole Antifungals in Human Plasma. Antimicrobial Agents and Chemotherapy, 2013, 57, 484-489.	3.2	32
88	Small intestinal motor patterns in critically ill patients after major abdominal surgery. American Journal of Gastroenterology, 2001, 96, 2418-2426.	0.4	31
89	Mushroom intolerance: a novel dietâ€“gene interaction in Crohn's disease. British Journal of Nutrition, 2009, 102, 506.	2.3	31
90	A Noninferiority Randomized Clinical Trial of the Use of the Smartphone-Based Health Applications IBDsmart and IBDoc in the Care of Inflammatory Bowel Disease Patients. Inflammatory Bowel Diseases, 2020, 26, 1098-1109.	1.9	31

#	Article	IF	Citations
91	Current relevance of pharmacogenetics in immunomodulation treatment for Crohn's disease. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1546-1554.	2.8	28
92	Thiopurine Therapy in Inflammatory Bowel Diseases: Making New Friends Should Not Mean Losing Old Ones. Gastroenterology, 2019, 156, 11-14.	1.3	27
93	A multiplexed allele-specific polymerase chain reaction assay for the detection of common thiopurine S-methyltransferase (TPMT) mutations. Clinica Chimica Acta, 2004, 341, 49-53.	1.1	26
94	The population pharmacokinetics of allopurinol and oxypurinol in patients with gout. European Journal of Clinical Pharmacology, 2013, 69, 1411-1421.	1.9	26
95	The effect of aminoglycoside-induced adaptive resistance on the antibacterial activity of other antibiotics against Pseudomonas aeruginosa in vitro. Journal of Antimicrobial Chemotherapy, 1996, 38, 853-858.	3.0	25
96	Association of DLG5 variants with inflammatory bowel disease in the New Zealand caucasian population and meta-analysis of the DLG5 R30Q variant. Inflammatory Bowel Diseases, 2007, 13, 1069-1076.	1.9	25
97	Lack of association between HLA-G 14 bp insertion/deletion polymorphism and response to long-term therapy with methotrexate response in rheumatoid arthritis: Table 1. Annals of the Rheumatic Diseases, 2009, 68, 154-155.	0.9	25
98	Interactions among genes influencing bacterial recognition increase IBD risk in a population-based New Zealand cohort. Human Immunology, 2009, 70, 440-446.	2.4	25
99	Thirteen Years' Experience of Pharmacokinetic Monitoring and Dosing of Busulfan. Therapeutic Drug Monitoring, 2014, 36, 86-92.	2.0	24
100	Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab. Therapeutic Drug Monitoring, 2016, 38, 32-41.	2.0	24
101	The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial. Arthritis Research and Therapy, 2017, 19, 283.	3.5	24
102	Improved efficacy with nonsimultaneous administration of first doses of gentamicin and ceftazidime in vitro. Antimicrobial Agents and Chemotherapy, 1995, 39, 132-136.	3.2	23
103	Single nucleotide polymorphisms in human Paneth cell defensin A5 may confer susceptibility to inflammatory bowel disease in a New Zealand Caucasian population. Digestive and Liver Disease, 2008, 40, 723-730.	0.9	22
104	Nucleotide-binding oligomerization domain containing 1 (NOD1) haplotypes and single nucleotide polymorphisms modify susceptibility to inflammatory bowel diseases in a New Zealand caucasian population: a case-control study. BMC Research Notes, 2009, 2, 52.	1.4	22
105	A Population Pharmacokinetic Model for Low-Dose Methotrexate and its Polyglutamated Metabolites in Red Blood Cells. Clinical Pharmacokinetics, 2013, 52, 475-485.	3.5	22
106	Maternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonates. Alimentary Pharmacology and Therapeutics, 2021, 53, 810-820.	3.7	22
107	Aminoglycoside toxicity and relation to dose regimen. Toxicological Reviews, 1994, 13, 207-34.	0.4	22
108	A Method to Exploit the Structure of Genetic Ancestry Space to Enhance Case-Control Studies. American Journal of Human Genetics, 2016, 98, 857-868.	6.2	21

#	Article	IF	Citations
109	â€˜It feels like being trapped in an abusive relationshipâ€™: bullying prevalence and consequences in the New Zealand senior medical workforce: a cross-sectional study. BMJ Open, 2018, 8, e020158.	1.9	21
110	Vitamin D receptor gene polymorphism associated with inflammatory bowel disease in New Zealand males. Alimentary Pharmacology and Therapeutics, 2011, 33, 855-856.	3.7	20
111	Therapeutic drug monitoring in rheumatic diseases: utile or futile?. Rheumatology, 2014, 53, 988-997.	1.9	20
112	Tumor Necrosis Factor Receptor Superfamily, Member 1B Haplotypes Increase or Decrease the Risk of Inflammatory Bowel Diseases in a New Zealand Caucasian Population. Gastroenterology Research and Practice, 2009, 2009, 1-9.	1.5	19
113	Genetic variations in matrix metalloproteinases may be associated with increased risk of ulcerative colitis. Human Immunology, 2011, 72, 1117-1127.	2.4	18
114	Smoking behaviour modifies IL23râ€associated disease risk in patients with Crohn's disease. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 299-307.	2.8	18
115	NOD2 and ATG16L1 polymorphisms affect monocyte responses in Crohn's disease. World Journal of Gastroenterology, 2011, 17, 2829-37.	3.3	18
116	Penile and clitoral stimulation for faecal incontinence: external application of a bipolar electrode for patients with faecal incontinence. Colorectal Disease, 2004, 6, 54-57.	1.4	17
117	Individualising the dose of allopurinol in patients with gout. British Journal of Clinical Pharmacology, 2017, 83, 2015-2026.	2.4	17
118	Cost-effectiveness of therapeutic drug monitoring in inflammatory bowel disease. Current Opinion in Pharmacology, 2020, 55, 41-46.	3.5	17
119	Macrophage migration inhibitory factor gene polymorphisms in inflammatory bowel disease: An association study in New Zealand Caucasians and meta-analysis. World Journal of Gastroenterology, 2013, 19, 6656.	3.3	17
120	Measurement of thiopurine methyl transferase activity guides dose-initiation and prevents toxicity from azathioprine. New Zealand Medical Journal, 2005, 118, U1324.	0.5	17
121	Assessment of the Relationship Between Methotrexate Polyglutamates in Red Blood Cells and Clinical Response in Patients Commencing Methotrexate for Rheumatoid Arthritis. Clinical Pharmacokinetics, 2014, 53, 1161-1170.	3.5	16
122	Coagulation assays and plasma fibrinogen concentrations in realâ€world patients with atrial fibrillation treated with dabigatran. British Journal of Clinical Pharmacology, 2014, 78, 630-638.	2.4	16
123	CARD15 allele frequency differences in New Zealand Maori: ancestry specific susceptibility to Crohn's disease in New Zealand?. Gut, 2006, 55, 580-580.	12.1	15
124	Association of FcgR2a, but not FcgR3a, with inflammatory bowel diseases across three Caucasian populationsâ€. Inflammatory Bowel Diseases, 2010, 16, 2080-2089.	1.9	15
125	Perspective on dabigatran etexilate dosing: why not follow standard pharmacological principles?. British Journal of Clinical Pharmacology, 2012, 74, 734-740.	2.4	15
126	Ileal disease is associated with surgery for perianal disease in a population-based Crohn's disease cohort. British Journal of Surgery, 2010, 97, 1103-1109.	0.3	14

#	Article	IF	Citations
127	A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis. European Journal of Clinical Pharmacology, 2017, 73, 71-78.	1.9	14
128	SLC11A1polymorphisms in inflammatory bowel disease andMycobacterium aviumsubspeciesparatuberculosisstatus. World Journal of Gastroenterology, 2010, 16, 5727.	3.3	14
129	Genetic polymorphism and outcomes with azathioprine and 6-mercaptopurine. Toxicological Reviews, 2000, 19, 293-312.	0.4	14
130	Perianal Disease Combined With NOD2 Genotype Predicts Need for IBD-related Surgery in Crohnâ€™s Disease Patients From a Population-based Cohort. Journal of Clinical Gastroenterology, 2013, 47, 242-245.	2.2	13
131	Comparison of intracellular methotrexate kinetics in red blood cells with the kinetics in other cell types. British Journal of Clinical Pharmacology, 2014, 77, 493-497.	2.4	13
132	Late-onset Rise of 6-MMP Metabolites in IBD Patients on Azathioprine or Mercaptopurine. Inflammatory Bowel Diseases, 2018, 24, 892-896.	1.9	13
133	Lack of Clinically Significant Interference by Spironolactone With the AxSym Digoxin II Assay. Therapeutic Drug Monitoring, 2003, 25, 112-113.	2.0	12
134	Comment: Breast-feeding During Maternal Use of Azathioprine. Annals of Pharmacotherapy, 2007, 41, 719-720.	1.9	12
135	Consolidation of Evidence for Association of the KIAA1109-TENR-IL2-IL21 rs6822844 Variant With Crohn's Disease. American Journal of Gastroenterology, 2010, 105, 1204-1205.	0.4	12
136	Prospective, randomized, controlled study comparing two dosing regimens of gentamicin/oral ciprofloxacin switch therapy for acute pyelonephritis. Clinical Nephrology, 1996, 46, 183-6.	0.7	12
137	The therapeutic monitoring of antimicrobial agents. British Journal of Clinical Pharmacology, 2001, 52, 35-43.	2.4	11
138	Rapid detection of common CARD15 variants in patients with inflammatory bowel disease. Molecular Diagnosis and Therapy, 2004, 8, 101-105.	1.1	11
139	Dosing of dabigatran etexilate in relation to renal function and drug interactions at a tertiary hospital. Internal Medicine Journal, 2013, 43, 778-783.	0.8	11
140	The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool. British Journal of Clinical Pharmacology, 2018, 84, 937-943.	2.4	11
141	Aminoglycoside dosing: time to change. Australian and New Zealand Journal of Medicine, 1994, 24, 359-361.	0.5	9
142	Gastrointestinal: Mycobacterium avium paratuberculosis and Crohn's disease. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 1943-1943.	2.8	9
143	Allopurinolâ€“thiopurine combination therapy in inflammatory bowel disease: are there genetic clues to this puzzle?. Pharmacogenomics, 2010, 11, 1505-1508.	1.3	9
144	Determination of imatinib and its active metabolite N-desmethyl imatinib in human plasma by liquid chromatography/tandem mass spectrometry. Analytical and Bioanalytical Chemistry, 2012, 404, 2091-2096.	3.7	9

#	Article	IF	Citations
145	Deterministic identifiability of population pharmacokinetic and pharmacokineticâ€“pharmacodynamic models. Journal of Pharmacokinetics and Pharmacodynamics, 2017, 44, 415-423.	1.8	9
146	How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose. Arthritis Research and Therapy, 2018, 20, 255.	3.5	9
147	Lower oesophageal sphincter tone increases after induction of anaesthesia in pigs with full stomach. Canadian Journal of Anaesthesia, 1998, 45, 479-482.	1.6	8
148	Infliximab and adalimumab concentrations and antiâ€drug antibodies in inflammatory bowel disease control using New Zealand assays. Internal Medicine Journal, 2019, 49, 513-518.	0.8	8
149	Small intestinal motor patterns in critically ill patients after major abdominal surgery. American Journal of Gastroenterology, 2001, 96, 2418-2426.	0.4	8
150	Macro-alkaline phosphatase due to IgG Îº complex: demonstration with polyethylene glycol precipitation and immunofixation. Annals of Clinical Biochemistry, 2002, 39, 523-525.	1.6	7
151	Beyond TPMT: genetic influences on thiopurine drug responses in inflammatory bowel disease. Personalized Medicine, 2008, 5, 233-248.	1.5	7
152	PACSIN2 Does Not Influence Thiopurine-Related Toxicity In Patients With Inflammatory Bowel Disease. American Journal of Gastroenterology, 2014, 109, 925-927.	0.4	7
153	Lansoprazole pharmacokinetics differ in patients with oesophagitis compared to healthy volunteers. Alimentary Pharmacology and Therapeutics, 1999, 13, 1215-1219.	3.7	6
154	Aminoglycoside Dosage Regimens After Therapeutic Drug Monitoring. Clinical Pharmacokinetics, 2002, 41, 791-792.	3.5	6
155	An Envirogenomic Signature Is Associated with Risk of IBD-Related Surgery in a Population-Based Crohnâ€™s Disease Cohort. Journal of Gastrointestinal Surgery, 2013, 17, 1643-1650.	1.7	6
156	Preanalytical stringency: what factors may confound interpretation of thiopurine S-methyl transferase enzyme activity?. Annals of Clinical Biochemistry, 2013, 50, 479-484.	1.6	6
157	Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomised controlled trial. Rheumatology, 2018, 57, 2183-2189.	1.9	6
158	Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urateâ€Lowering Responseâ€”In Search of a Minimum Effective Oxypurinol Concentration. Clinical and Translational Science, 2020, 13, 110-115.	3.1	6
159	A nationwide survey on therapeutic drug monitoring of antiâ€tumour necrosis factor agents for inflammatory bowel disease. Internal Medicine Journal, 2021, 51, 341-347.	0.8	6
160	Comparison of Risk Scoring Systems in Hospitalised Patients who Develop Upper Gastrointestinal Bleeding. GastroHep, 2021, 3, 5-11.	0.6	6
161	Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab in Utero: A Prospective Cohort Study in 107 Children. Journal of Crohn's and Colitis, 2022, 16, 1835-1844.	1.3	6
162	Determination of perhexiline and its metabolite hydroxyperhexiline in human plasma by liquid chromatography/tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 3025-3030.	2.3	5

#	Article	IF	Citations
163	Rifampicin and dabigatran etexilate: a place for laboratory coagulation monitoring. British Journal of Clinical Pharmacology, 2013, 75, 569-570.	2.4	5
164	Biological variation of thiopurine methyltransferase enzyme activity: when has a significant change taken place?. Annals of Clinical Biochemistry, 2013, 50, 473-478.	1.6	5
165	Exome sequencing and array-based comparative genomic hybridisation analysis of preferential 6-methylmercaptopurine producers. Pharmacogenomics Journal, 2015, 15, 414-421.	2.0	5
166	Single Nucleotide Polymorphisms in IL4, OCTN1 and OCTN2 Genes in Association with Inflammatory Bowel Disease Phenotypes in a Caucasian Population in Canterbury, New Zealand. The Open Gastroenterology Journal, 2008, 2, 50-56.	0.1	5
167	Clozapine-Induced Gastrointestinal Hypomotility. Australasian Psychiatry, 2011, 19, 450-451.	0.7	4
168	Nonsynonymous Polymorphism in Guanine Monophosphate Synthetase Is a Risk Factor for Unfavorable Thiopurine Metabolite Ratios in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 2606-2612.	1.9	4
169	A Pilot Randomized Controlled Double-Blind Trial of High- Versus Low-Dose Weekly Folic Acid in People With Rheumatoid Arthritis Receiving Methotrexate. Journal of Clinical Rheumatology, 2019, 25, 284-287.	0.9	4
170	Thiopurine Treatment in??Inflammatory Bowel??Disease. Clinical Pharmacokinetics, 2007, 46, 803-804.	3.5	3
171	Evidence that glioma-associated oncogene homolog 1 is not a universal risk gene for inflammatory bowel disease in Caucasians. Genes and Immunity, 2010, 11, 509-514.	4.1	3
172	Comment on: â€œEffect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Studyâ€. Clinical Pharmacokinetics, 2017, 56, 207-208.	3.5	3
173	Clinical decision support in a hospital electronic prescribing system informed by local data: experience at a tertiary New Zealand centre. Internal Medicine Journal, 2020, 50, 1225-1231.	0.8	3
174	Rapid Detection of Common CARD15 Variants in Patients with Inflammatory Bowel Disease. Molecular Diagnosis and Therapy, 2004, 8, 101-105.	1.1	3
175	The scratch test for identifying the lower liver edge is at least as accurate as percussion and is significantly more effective for young trainees-a randomised comparative trial. New Zealand Medical Journal, 2016, 129, 53-63.	0.5	3
176	Independent Replication of an Association of CNVR7113.6 with CrohnÊ¼s Disease in Caucasians. Inflammatory Bowel Diseases, 2012, 18, 305-311.	1.9	1
177	P630 A non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDocÂ® in the care of inflammatory bowel disease patients. Journal of Crohn's and Colitis, 2019, 13, S432-S433.	1.3	1
178	A 1 g dose of intravenous iron is sufficient to treat iron deficiency anaemia. Internal Medicine Journal, 2020, 50, 1563-1566.	0.8	1
179	Association of the protein-tyrosine phosphatase nonreceptor type substrate 1 (PTPNS1) gene with inflammatory bowel disease. Inflammatory Bowel Diseases, 2011, 17, E19-E21.	1.9	0
180	Letter: <scp>TPMT</scp> â€“ not all that glitters is gold; authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2012, 36, 209-210.	3.7	0

#	Article	IF	Citations
181	Sa1269 Adjunctive Allopurinol in Azathioprine/6-Mercaptopurine Non-Responders Optimises 6-Thioguanine Nucleotide Production and Improves Clinical Outcomes in Inflammatory Bowel Disease: The Prospective, Multicentre, Double Blind, Dose-Ranging AAA Study. Gastroenterology, 2015, 148, S-277.	1.3	0
182	AB1031â€...Anti-drug antibodies: assay performance in patients treated with ANTI-TNF biodrugs. , 2017, , .		0
183	Editorial: vedolizumab as a treatment and cause of extraâ€intestinal manifestations of inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2018, 47, 535-536.	3.7	0
184	Mo1290 â€“ Comparison of Risk Scoring Systems in Hospitalized Patients that Develop Upper Gastrointestinal Bleeding. Gastroenterology, 2019, 156, S-749.	1.3	0
185	P523 Endoscopic balloon dilatation is safe and has a high success rate in patients with stricturing Crohnâ€™s disease. Journal of Crohn's and Colitis, 2019, 13, S374-S374.	1.3	0
186	Tu1496 THE ABC SCORE ACCURATELY PREDICTS MORTALITY IN HOSPITALIZED PATIENTS THAT DEVELOP UPPER GASTROINTESTINAL BLEEDING. Gastrointestinal Endoscopy, 2020, 91, AB590-AB591.	1.0	0
187	New Zealand Society of Gastroenterology Guidelines on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. New Zealand Medical Journal, 2019, 132, 46-62.	0.5	0